Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients
| dc.rights.license | open | en_US |
| dc.contributor.author | SALMON, D. | |
| dc.contributor.author | TRIMOULET, P. | |
| dc.contributor.author | GILBERT, C. | |
| dc.contributor.author | SOLAS, C. | |
| dc.contributor.author | LAFOURCADE, E. | |
| dc.contributor.author | CHAS, J. | |
| dc.contributor.author | PIROTH, L. | |
| dc.contributor.author | LACOMBE, K. | |
| dc.contributor.author | KATLAMA, C. | |
| dc.contributor.author | PEYTAVIN, G. | |
| dc.contributor.author | AUMAITRE, H. | |
| dc.contributor.author | ALRIC, L. | |
| dc.contributor.author | BOUE, F. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | MORLAT, Philippe | |
| dc.contributor.author | POIZOT-MARTIN, I. | |
| dc.contributor.author | BILLAUD, E. | |
| dc.contributor.author | ROSENTHAL, E. | |
| dc.contributor.author | NAQVI, A. | |
| dc.contributor.author | MIAILHES, P. | |
| dc.contributor.author | BANI-SADR, F. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | ESTERLE, Laure | |
| dc.contributor.author | CARRIERI, P. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | DABIS, Francois | |
| dc.contributor.author | SOGNI, P. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | WITTKOP, Linda | |
| dc.date.accessioned | 2021-01-04T14:32:00Z | |
| dc.date.available | 2021-01-04T14:32:00Z | |
| dc.date.issued | 2018-11-27 | |
| dc.identifier.issn | 1948-5182 (Print) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/23625 | |
| dc.description.abstractEn | AIM: To describe factors associated with treatment failure and frequency of resistance-associated substitutions (RAS). METHODS: Human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfected patients starting a first direct-acting antiviral (DAA) regimen before February 2016 and included in the French ANRS CO13 HEPAVIH cohort were eligible. Failure was defined as: (1) non-response [HCV-RNA remained detectable during treatment, at end of treatment (EOT)]; and (2) relapse (HCV-RNA suppressed at EOT but detectable thereafter). Sequencing analysis was performed to describe prevalence of drug class-specific RAS. Factors associated with failure were determined using logistic regression models. RESULTS: Among 559 patients, 77% had suppressed plasma HIV-RNA < 50 copies/mL at DAA treatment initiation, 41% were cirrhotic, and 68% were HCV treatment-experienced. Virological treatment failures occurred in 22 patients and were mainly relapses (17, 77%) then undefined failures (3, 14%) and non-responses (2, 9%). Mean treatment duration was 16 wk overall. Post-treatment NS3, NS5A or NS5B RAS were detected in 10/14 patients with samples available for sequencing analysis. After adjustment for age, sex, ribavirin use, HCV genotype and treatment duration, low platelet count was the only factor significantly associated with a higher risk of failure (OR: 6.5; 95%CI: 1.8-22.6). CONCLUSION: Only 3.9% HIV-HCV coinfected patients failed DAA regimens and RAS were found in 70% of those failing. Low platelet count was independently associated with virological failure. | |
| dc.language.iso | EN | en_US |
| dc.subject.en | CREDIM | |
| dc.subject.en | MORPH3Eus | |
| dc.subject.en | ANRS CO13 HEPAVIH | |
| dc.title.en | Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients | |
| dc.title.alternative | World J Hepatol | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.4254/wjh.v10.i11.856 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 30533186 | en_US |
| bordeaux.journal | World journal of hepatology | en_US |
| bordeaux.page | 856-866 | en_US |
| bordeaux.volume | 10 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - U1219 | en_US |
| bordeaux.issue | 11 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.team | CREDIM | en_US |
| bordeaux.team | MORPH3Eus | en_US |
| bordeaux.team | ANRS CO13 HEPAVIH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.export | false | |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=World%20journal%20of%20hepatology&rft.date=2018-11-27&rft.volume=10&rft.issue=11&rft.spage=856-866&rft.epage=856-866&rft.eissn=1948-5182%20(Print)&rft.issn=1948-5182%20(Print)&rft.au=SALMON,%20D.&TRIMOULET,%20P.&GILBERT,%20C.&SOLAS,%20C.&LAFOURCADE,%20E.&rft.genre=article |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||